Skip to main content

Milestone 6.C

Identify, characterize, and complete early validation for at least 6 novel therapeutic targets for AD and AD-related dementias (a minimum of 3 targets for pre-symptomatic and early stage disease and a minimum of 3 for advanced disease). These efforts should include therapeutic targets for the neuropsychiatric and behavioral disturbances in AD and ADRDs.


Success Criteria

  • Validation based on availability of the following for each novel target: a systems-level understanding of the gene, protein and metabolic networks within which they operate, one or more cell based/animal models that are freely available to the research community, a quantitative assessment of the integrative response to the modulation of the target in one or more model organisms, and identification of pharmacodynamic biomarker(s) for target engagement.


Research Implementation Area
Drug Development - Novel Targets
Timeline
2014–2020
Status
Complete

Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations